Radiopharmaceuticals have been utilized for men with advanced prostate cancer for
decades. Older agents, seldom used today, provided palliation for bone metastatic pain. In …

Context Prostate-specific membrane antigen (PSMA) is a promising, novel theranostic target
in advanced prostate cancer (PCa). Multiple PSMA-targeted therapies are currently in …

Background: Promising therapeutic results of the prostate-specific membrane antigen
(PSMA) ligand have been shown when labelling with lutetium-177 (177 Lu). We performed a …

Targeted alpha particle therapy (TAT) has emerged as a promising strategy for the treatment
of prostate cancer (PCa). Actinium-225 (225 Ac), a potent alpha-emitting radionuclide, may …

Introduction The Prostate Cancer Foundation (PCF) convened a PSMA‐Directed
Radionuclide Scientific Working Group on November 14, 2017, at Weill Cornell Medicine …

Objective To examine the clinical benefit of Lu-177-PSMA-617 radioligand therapy for
patients with metastatic castration-resistant prostate cancer (mCRPC). Patients and Methods …

Prostate-specific membrane antigen (PSMA) is highly expressed on both benign and
malignant prostatic tissue. Prostate-specific membrane antigen–directed therapy is …

Introduction: Progress in the understanding of molecular events of carcinogenesis and
cancer evolution as well as the identification of tumor antigens has led to the development of …

Radiopharmaceuticals used in the treatment of castrate-resistant prostate cancer are
reviewed herein with an emphasis on sequential and combination therapies. Four bone …

Weitere Personen waren an der Erstellung der vorliegenden Arbeit nicht beteiligt.
Insbesondere habe ich nicht die Hilfe einer Promotionsberaterin/eines Promotionsberaters …